Food and Drug Administration: FDAs Concerns With Unapproved GLP-1 Drugs Used for Weight Loss GLP-1 Agonists
Demonstrated an acceptable safety profile, with gastrointestinal events being the most frequently reported adverse effects
Post-reset nutrition When restarting medication after a reset, return to the same nutrition principles you followed during initial treatment
GLP-1 treatments may require adjustments to other prescriptions, so staying organized helps prevent any conflicts or missed doses
These might include: Blood tests to assess for coeliac disease, inflammatory markers, or thyroid function Breath tests for lactose intolerance or small intestinal bacterial overgrowth Abdominal imaging (ultrasound or CT) if structural abnormalities are suspected Faecal calprotectin if inflammatory bowel disease is a concern Referral to gastroenterology for specialist assessment if symptoms persist despite initial management The MHRA's Yellow Card scheme allows patients and healthcare professionals to report suspected side effects of medications, including GLP-1 agonists
Metformin Represses Glucose Starvation Induced Autophagic Response in Microvascular Endothelial Cells and Promotes Cell Death